A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Link
https://link.springer.com/content/pdf/10.1007/s40264-020-00944-1.pdf
Reference72 articles.
1. Eichler H-G, Baird L, Barker R, et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther. 2015;97(3):234–46.
2. Liberti L, Bujar M, Breckenridge A, et al. FDA facilitated regulatory pathways: visualizing their characteristics, development, and authorization timelines. Front Pharmacol. 2017;8:161.
3. Pullman D, Wang X. Adaptive designs, informed consent, and the ethics of research. Control Clin Trials. 2001;22(3):203–10.
4. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation. 2009;119(4):597–605.
5. Nelson NJ. Adaptive clinical trial design: has its time come? J Natl Cancer Inst. 2010;102(16):1217–8.
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations;Drug Safety;2024-08-05
2. Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases;Clinical and Translational Science;2024-08
3. Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control;Scientific Reports;2024-06-25
4. Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor (EGFR)-Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine Kinase Inhibitor: A Real-World External Comparator Study;Cancers;2024-06-07
5. Single-arm clinical trials: design, ethics, principles;BMJ Supportive & Palliative Care;2024-06-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3